Zymeworks Quote - ZYME

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

15.25

Bid

15.27

Offer

15.96

Volume

740,777

14.99 Day's Range 16.5065

7.97 52 Week Range 17.70

Market Cap

1.05B

Previous Close

14.78

Open

16.5065

Last Trade

15.62

Last Trade Time

Financial Volume

US$ 11,361,186

VWAP

15.3369

Average Volume (3m)

501,994

Shares Outstanding

68,877,526

Dividend Yield

PE Ratio

-8.72

Earnings Per Share (EPS)

-1.72

Revenue

76.01M

Net Profit

-118.67M

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.zymeworks.com

Headquarters

Wilmington, Delaware, USA

Founded

Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was US$14.78. Over the last year, Zymeworks shares have traded in a share price range of US$ 7.97 to US$ 17.70.

Zymeworks currently has 68,877,526 shares in issue. The market capitalisation of Zymeworks is US$1.02 billion. Zymeworks has a price to earnings ratio (PE ratio) of -8.72.

Form 4 - Statement of changes in beneficial ownership of securities

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T...

Form 8-K - Current report

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective...

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

VANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.73	5.02754820937	14.52	15.25	13.771	455158	14.61966218	CS
4	1.07	7.54583921016	14.18	15.25	12.43	525760	13.78775979	CS
12	2.45	19.140625	12.8	17.7	12.39	501994	14.29794074	CS
26	6.82	80.9015421115	8.43	17.7	8.32	612663	12.26656376	CS
52	4.85	46.6346153846	10.4	17.7	7.97	605491	11.11051126	CS
156	8.87	139.028213166	6.38	17.7	6.015	619939	9.63816715	CS
260	8.87	139.028213166	6.38	17.7	6.015	619939	9.63816715	CS

ZYME - Frequently Asked Questions (FAQ)

What is the current Zymeworks share price?

The current share price of Zymeworks is US$ 15.25

How many Zymeworks shares are in issue?

Zymeworks has 68,877,526 shares in issue

What is the market cap of Zymeworks?

The market capitalisation of Zymeworks is USD 1.02B

What is the 1 year trading range for Zymeworks share price?

Zymeworks has traded in the range of US$ 7.97 to US$ 17.70 during the past year

What is the PE ratio of Zymeworks?

The price to earnings ratio of Zymeworks is -8.72

What is the cash to sales ratio of Zymeworks?

The cash to sales ratio of Zymeworks is 13.62

What is the reporting currency for Zymeworks?

Zymeworks reports financial results in USD

What is the latest annual turnover for Zymeworks?

The latest annual turnover of Zymeworks is USD 76.01M

What is the latest annual profit for Zymeworks?

The latest annual profit of Zymeworks is USD -118.67M

What is the registered address of Zymeworks?

The registered address for Zymeworks is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Zymeworks website address?

The website address for Zymeworks is www.zymeworks.com

Which industry sector does Zymeworks operate in?

Zymeworks operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
CRNCCerence Inc	US$ 19.33 (143.76%)	161.8M
KITTNauticus Robotics Inc	US$ 3.8249 (140.56%)	104.8M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
HWHHWH International Inc	US$ 0.4621 (-28.80%)	7.43M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5.69 (-26.30%)	24.77M
RAINRain Enhancement Technologies Holdco Inc	US$ 5.59 (-23.42%)	161.15k
PTLEPTL Ltd	US$ 9.35 (-23.30%)	1.04M
NXUNXU Inc	US$ 0.725868 (-22.78%)	7.59M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
TGLTreasure Global Inc	US$ 0.382 (101.58%)	337.5M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NVDANVIDIA Corporation	US$ 144.47 (4.45%)	230.01M